Form 4: Phathom Pharmaceuticals CEO Acquires Performance Shares and Stock Options

Steven L. Basta, President and CEO of Phathom Pharmaceuticals, acquired 360,000 performance shares and 1,085,000 stock options on April 3, 2025.

Summary

• On April 3, 2025, Steven L. Basta, the President and CEO of Phathom Pharmaceuticals, acquired 360,000 performance shares.
• These performance shares represent a contingent right to receive one share of Phathom Pharmaceuticals common stock each.
• The performance stock units will vest based on the achievement of stock price hurdles and service-based vesting requirements over a four-year period following the grant date.
• Basta also acquired 1,085,000 stock options with an exercise price of $5.01.
• These options vest with respect to 25% of the shares on April 3, 2026, and the remaining shares vest in equal monthly installments over the following three years, contingent upon continuous service to the company.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of equity-based compensation is generally viewed favorably as it aligns management's interests with shareholders. The vesting schedules promote long-term commitment.

Positives

• The acquisition of performance shares and stock options aligns the CEO's interests with those of the shareholders, incentivizing him to drive stock price appreciation.
• The vesting schedules for both the performance shares and stock options encourage long-term commitment from the CEO.

Risks

• The vesting of performance shares is contingent on achieving stock price hurdles, which may not be met.
• The value of the stock options is dependent on the stock price exceeding the exercise price of $5.01.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules of the performance shares and stock options.

Industry Context

Granting stock options and performance shares is a common practice in the pharmaceutical industry to incentivize executives and align their interests with shareholders. The specific terms of the grants (vesting schedule, performance hurdles) are tailored to the company's specific goals and circumstances.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the pharmaceutical industry.
• Companies like Amgen, Gilead, and Biogen also utilize stock options and performance-based equity awards to incentivize their executives.
• The vesting schedules and performance hurdles are typically designed to align with the company's long-term strategic goals and shareholder value creation.

Stakeholder Impact

• Shareholders: The equity grants aim to align management's interests with shareholder value creation.
• Employees: The grants may have a positive impact on employee morale by demonstrating the company's commitment to its leadership.

Key Dates

Keywords

Phathom Pharmaceuticals, Steven L. Basta, performance shares, stock options, executive compensation, vesting, equity, PHAT